Rexulti vs Spravato
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Rexulti | US Spravato | |
|---|---|---|
| Generic name | brexpiprazole | esketamine |
| Drug class | Atypical Antipsychotic | NMDA Receptor Antagonist |
| Treats | Major depression (add-on), schizophrenia, agitation in dementia | Treatment-resistant depression |
| Category | Mental Health | Mental Health |
| Manufacturer | Otsuka/Lundbeck | Janssen |
| Year approved | 2015 | 2019 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $170M | — |
| Common side effects | Weight gain, Restlessness, Drowsiness, Movement disorders | Sedation, Dissociation, Abuse and misuse potential, Increased blood pressure |
Frequently asked questions
Is Rexulti or Spravato better?
Neither is universally "better." Rexulti (brexpiprazole) and Spravato (esketamine) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Rexulti and Spravato?
Rexulti is a Atypical Antipsychotic made by Otsuka/Lundbeck, while Spravato is a NMDA Receptor Antagonist made by Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Rexulti has the larger estimated TV advertising budget of the two.